Our Research Centres
At the heart of our strategy to beat cancer sooner is a network of translational centres delivering world-leading research that accelerates the transition of lab-based discovery science to the clinic for the benefit of people affected by cancer.
Our Centres drive local collaborations between universities, NHS hospitals, and other research organisations. Together, they operate as a network which plays a key role in delivering our strategic objectives, with different Centres contributing their expertise in different tumour sites and research themes.
We award Centre status to locations performing the highest quality cancer research, providing over £200 million of infrastructure investment funding for technical staff, equipment, training and running costs.
Centres review & funding periods
We fund our centres on a five-year cycle, with the current funding cycle running from April 2017 to March 2022. At the end of the funding cycle, we convene an independent, international Panel to assess the performance of each centre, applications from potential new centres, and the network as a whole.
Prospective applicants for Centre status at the next funding cycle (2022-27) should contact the CRUK Centres and Institutes team (email@example.com) to discuss their eligibility. New applications could be considered up to 31st March 2021 with final funding decisions made in late 2021.
Directory of Centres
|Barts Cancer Institute||Nick Lemoine||Cancer Prevention and Risk Reduction; Screening and Early Diagnosis; Genetics and Cancer Evolution; Therapeutic Innovation|
|Birmingham||Ben Willcox and Gary Middleton||Cancer Immunology; Cancer Genomics; Tumour Microenvironment|
|Cambridge||Richard Gilbertson||Oesophageal, Lung, Breast, Blood, Brain, Ovarian, Paediatric and Pancreatic Cancers; Advanced Cancer Imaging; Early Detection; Onco-Innovation|
|City of London||Tariq Enver||Development, manufacture and precision application of biological therapies|
|Convergence Science (ICR-Imperial)||Axel Behrens||Convergence Therapeutics, Data Science, Early Detection, Therapy Monitoring|
|Edinburgh||Ian Tomlinson and Charlie Gourley||Lifestyle, Risk and Prevention; Stem Cells; Phenomics Drug Discovery; Stratified Therapies|
|Glasgow||Owen Sansom||Precision Oncology; Cancer Immunology; Invasion and Metastasis; Cancer Metabolism; Radiotherapy|
|Imperial College London||George Hanna||Prevention and Screening; Precision Oncology|
|Institute of Cancer Research, London||Paul Workman||Image-Guided Therapies; Systemic Therapies; Big Data|
|King's Health Partners, London||Peter Parker||Tumour Microenvironment; Immunotherapy; Patient Profiling and Imaging|
|Manchester||Rob Bristow||Experimental Cancer Medicine; Biomarker Discovery and Translation; Radiotherapy; Molecular Pathology; Prevention and Early Detection|
|Newcastle||Ruth Plummer||Novel Therapeutics; Clinical Pharmacology; Biomarkers; Early Phase Clinical Trials|
|Oxford||Mark Middleton and Tim Elliot||Localised Therapy; Clinical Trial Delivery; Stratification; Health Data|
|Southampton||Peter Johnson||Immuno-oncology; Immunotherapy; Tumour Microenvironment; Breast Cancer; Lymphoma|
|University College London||Tariq Enver and Daniel Hochhauser||Cancer Immunotherapy; Lung Cancer; Cancers of the Nervous System; Blood Cancers|
Dr Brooke Lumicisi
Research Programme Manager – Lead for CRUK Centres
We fund a network of state-of-the-art facilities at 90 institutions across the UK. From basic science and drug discovery to experimental medicine and clinical trials, our infrastructure enables research throughout the pipeline.
Are you looking for new opportunities to exchange ideas and interact more closely with other research groups?
The Cancer Research UK Open Lab Initiative has been launched to encourage CRUK Centre Network research groups, CRUK-funded laboratories, and other groups undertaking cancer-related research to hold joint group meetings online.
Our aim is to connect research groups with mutual or complementary interests to spark creative discussions, generate novel scientific ideas, and establish new research collaborations.